Provision of General Medical Services at Tollgate Practice

Nova Education Trust is a forward-thinking multi-academy trust committed to delivering exceptional educational outcomes across its family of Trusts. With a strong presence in the East Midlands, the Trust is driven by a shared vision to create transformational teaching and learning experiences that empower every young learner to thrive. Nova Education Trust is seeking to establish a compliant, scalable and outcome-focused Inclusion Centre service across its family of schools. The Trust is seeking a suitably qualified and experienced provider to deliver, manage and continuously develop Inclusion Centre services across one or more schools within the Trust. The service will provide targeted intervention, behaviour support, pastoral support and reintegration programmes for pupils who are at risk of suspension, permanent exclusion, disengagement from education, poor attendance or other barriers to learning. To access this competition: Registered: Login to https://suppliers.multiquote.com and view the opportunity CA18386. Not registered: Visit https://suppliers.multiquote.com then register and quote CA18386 as the reason for registration. Any queries please contact MultiQuote on 020 3920 8054.

Delivering interventions to children with speech, language, communication, or swallowing and eating needs to help them reach their full communication potential. This includes delivering direct interventions in line with a Child's Education, Health, and Care Plan (EHCP), as well as offering indirect support through professional training and parent/carer guidance. This provision will work across Young Hackney, Youth Justice Virtual School, Schools, and Early Years provision. This contract will include for the provision of Speech and Language Therapists as part of the Hackney Experts at Hand team, in line with requirements related to the Department for Education's Experts at Hand initiative. This initiative is seeking to improve the capability of mainstream education settings to meet the needs of children and young people with SEND more effectively, by providing a new route to access expert advice and support from health professionals. The contract start date is expected to be 1st April 2027 with an initial term of 3 years, and two extension options each of a year; for a total possible contract length of 5 years.

Please see tender documentation.

East Suffolk and North Essex NHS Foundation Trust (ESNEFT) is inviting qualified providers to express an interest to participate in a tender exercise for; Managed Service for the Provision of Renal Dialysis Services under the Provider Selection Regime To access this competition: Registered: Login to https://suppliers.multiquote.com and view the opportunity CA18304. Not registered: Visit https://suppliers.multiquote.com then register and quote CA18304 as the reason for registration. Any queries please contact MultiQuote on 020 3920 8054.

Delivering interventions that support children take part in everyday activities; ensuring they can care for themselves, undertake productive occupations (e.g., writing, learning), play, and have fun. The service will also equip parents/carers, and professionals with the tools and knowledge to support children with illnesses or Special Educational Needs and Disabilities (SEND). This provision will work across Hackney's Virtual School and Disabled Children's Service. This contract will include the provision of Occupational Therapists as part of the Hackney Experts at Hand team, in line with requirements related to the Department for Education's Experts at Hand initiative. This initiative is seeking to improve the capability of mainstream education settings to meet the needs of children and young people with SEND more effectively, by providing a new route to access expert advice and support from health professionals. The contract start date is expected to be 1st April 2027 with an initial term of 3 years, and two extension options each of a year; for a total possible contract length of 5 years.

The Trust is looking to appoint a supplier to provide CAMHs Tier 4 bed and associated services in the BNSSG area. To access this competition: Registered: Login to https://suppliers.multiquote.com and view the opportunity CA18336. Not registered: Visit https://suppliers.multiquote.com then register and quote CA18336 as the reason for registration. Any queries please contact MultiQuote on 020 3920 8054.

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…

Expected Outcome: This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as: The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scaling The absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes: By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a firmware stack (scheduler, controller, compiler), validated via hardware-agnostic benchmarks and hybrid photonic-HPC applications demonstrating classical-quantum crossover By 2030, delivery of a full-stack, high-connectivity photonic quantum computer, with modular scalability, integrated…